Aiming higher: upping our game in metastatic castration resistant prostate cancer management - CME

CME

Title: Aiming higher: upping our game in metastatic castration resistant prostate cancer management

Description: Prostate cancer (PC) is the most common form of malignancy among men in the U.S. with close to 314,000 new cases and over 35,000 deaths from PC annually. Over the past few decades, the death rates associated with PC have declined, likely due to changes in screening practices and improved treatment options. However, the incidence of PC overall has increased in recent years, and the incidence of mPC at the time of diagnosis is on the rise, accounting for about 8% of those diagnosed. And while patients with local or regional disease have 5-year survival rates close to 100%, that number decreases to 37% for patients with metastatic disease (mPC). Mortality aside, as mPC advances, patients often experience increasing symptom burden, such as persistent fatigue and bone pain, both of which can severely impact their overall quality of life (QoL).

Target Audience: HCPs including but not limited to: oncologists and urologists; physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other HCPs with an interest in or who may clinically encounter patients with mPC.

Learning Objectives

Recall the roles of castration status and biomarkers in personalizing the care plan for patients with mPC.
Summarize: first-line, later-line, and investigational pharmacotherapies for mPC; their mechanisms of action; and their current or anticipated place in therapy.
List the challenges and barriers to care associated with treating patients with mPC.
Formulate a treatment plan for a patient with mPC.

Keywords: Metastatic Prostate Cancer, castration-resistant prostate cancer (CRPC), prostate cancer

Disclosures and Disclaimers: As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Accredited Providers

Commercial Support

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	1 Credits	ACCME- Accreditation Council for Continuing Medical Education